Even though Sun et al. described a higher risk of lymph node metastasis, and distant metastasis with p16 under-expression but no changes in PFS or overall survival (OS) was noted [11]. This evidence concerns the gene CDKN2A and metastatic malignant neoplasm in the lymph nodes.